Brian Orelli
Freelance Writer and Analyst at The Motley Fool (U.S.)
Writer at Freelance
San Diego Contributing Correspondent at BiotechTV
Articles
-
1 day ago |
bioworld.com | Brian Orelli
Home » Abvance Therapeutics secures seed funding to limit glucose lows BioWorld briefs for June 26, 2025. BioWorld MedTech briefs for June 25, 2025. Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric... BioWorld Asia briefs for June 24, 2025 Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another.
-
2 weeks ago |
bioworld.com | Brian Orelli
Newco newsMosanna launches with $80M to develop its sleep apnea drugMosanna Therapeutics secured $80 million in a series A round to develop MOS-118 as a treatment for the nearly 1 billion people globally with obstructive sleep apnea (OSA). The company has completed the formulation work to make the drug into a nasal spray and the initial proof-of-concept animal studies and is now ready to enter clinical trials in patients with OSA. BioWorld Financings Newco news Neurology/psychiatric Series A
-
3 weeks ago |
bioworld.com | Brian Orelli
Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
-
3 weeks ago |
bioworld.com | Brian Orelli
Biontech trades half of bispecific BNT-327 to BMS for potential $11B+Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 billion. BNT-327 is in the hot new class of bispecific antibodies targeting programmed death-1 (PD-1) or its ligand (PD-L1) and vascular endothelial growth factor (VEGF).
-
1 month ago |
bioworld.com | Brian Orelli
Regeneron plans to buy 23andme from bankruptcy for $256MRegeneron Pharmaceuticals Inc. was the successful bidder for 23andme Holding Co.’s personal genome service, total health and research services business lines, including its biobank and associated assets, in the bankruptcy auction to sell 23andme's assets. BioWorld BioWorld MedTech Deals and M&A
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- Tweets
- DMs Open
Biotech investing would be more fun if pharmas would make more CVRs tradable. I understand why they don't bother as there's little (no?) benefit to them, but it sure would make things more interesting.
RT @BiotechTVHQ: 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Later today, BiotechTV will be kicking off its coverage of #ASCO25 with @AlbertBourla to discuss @pfizer's big…
Sunday is my 25th anniversary of being a Fool (a member -- not quite 25 years of work, yet). And I'm throwing myself a party on Fool24. Non-members can watch on the YouTube stream: https://t.co/irreZJiguj (make sure you're watching live as the stream starts earlier in the day)
